Linatra

Linagliptin, the active ingredient in Linatra, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive treatment plan.

GNH USA supplies Linatra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customer support includes regulatory documentation and logistics coordination.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycaemic control as part of diet and exercise therapy. - Monotherapy: lowers HbA1c when used alone in patients inadequately controlled by lifestyle alone. - Combination therapy: enhances glucose control when added to metformin, sulfonylureas, or insulin.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal discomfort reported in some patients. - Headache: transient headache occurring early in therapy. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhoea: loose stools, usually self-limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes, requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylactic reactions. - Hepatic injury: marked elevation of liver enzymes or jaundice.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: no dose adjustment required, but monitor renal function periodically. - Hepatic impairment: use with caution in patients with moderate liver disease; assess liver enzymes. - Cardiovascular risk: evaluate for heart failure symptoms, although no direct contraindication. - Pregnancy and lactation: avoid use unless potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin exposure. - Combination with insulin secretagogues (e.g., sulfonylureas) without dose adjustment: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may enhance hypoglycaemic effect. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Anticoagulants (e.g., warfarin): observe INR as linagliptin may affect metabolism.